What does CUSIP 29286M113 represent in this 13F holders report?

CUSIP 29286M113 is the security identifier for ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 used to aggregate holder disclosures.

How many institutions held ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 in Q4 2023?

21 institutional investors reported ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 for Q4 2023. Use the holders table for investor-level position and value details.

202 (ENGNW)

CUSIP: 29286M113

Q4 2023 13F Holders as of 31 Dec 2023

Security type / class: Equity / *W EXP 10/31/202
Total 13F shares: 4,440,160
Total 13F value: $3,691,565
Share change: +3,965,084
SEC-reported price per share: $0.85
Number of holders: 21
Value change: +$3,287,750
Number of buys: 20

Security key

29286M113

Report period

Q4 2023

Institutions

Top holders

ENGNW full security history Ownership snapshot Full 13F holder table enGene Therapeutics Inc. SEC filings enGene Therapeutics Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Forbion Growth Sponsor FE...

Disclosed value leader

—

Comparable rows

0/6

Latest evidence

30 Nov 2023

3/4/5 Some rows are evidence-backed but not safely comparable across classes. 6 rows are not safely comparable across share classes.

Quick read

SEC ownership evidence is available, but the rows are not safely comparable across share classes.

0 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Forbion Growth Sponsor FEAC I B.V.'s linked filing trail.

Detailed SEC evidence table Showing 1-6 of 6 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Forbion Growth Sponsor FEAC I B.V.	3/4/5 10%+ Owner 3/4/5	— mixed-class rows	— 5,502,338 shares mixed-class rows	—	31 Oct 2023
Forbion Capital Fund III Cooperatief U.A.	3/4/5 10%+ Owner 3/4/5	— class O/S missing	— 2,894,735 shares	—	31 Oct 2023
BVF PARTNERS L P/IL	3/4/5 10%+ Owner 3/4/5	— class O/S missing	— 104,257 shares	—	31 Oct 2023
Jason David Hanson	3/4/5 Chief Executive Officer, Director 3/4/5	— class O/S missing	— 512,826 shares	—	31 Oct 2023
Richard P. Bryce	3/4/5 Chief Medical Officer 3/4/5	— class O/S missing	— 153,000 shares	—	30 Nov 2023
James C. Sullivan	3/4/5 Chief Scientific Officer 3/4/5	— class O/S missing	— 118,509 shares	—	31 Oct 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

4,440,160

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders

Q4 2023 holders

Holder diff

Investor	Q3 2023 Shares	Q4 2023 Shares	Share Diff	Share Chg %	Q3 2023 value	Q4 2023 value	Value change	Value Chg %